Drugs / maxacalcitol

Trials 1 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00667576 Apr 2008 → Mar 2009 chronic kidney disease, secondary hyperparathyroidism of renal origin Abbott Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00990704 Comparator Oct 2009 → May 2010 secondary hyperparathyroidism of renal origin Abbott Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01341782 Comparator May 2011 → Apr 2012 secondary hyperparathyroidism AbbVie Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as maxacalcitol ClinicalTrials.gov intervention name — accepted as the source's own label NCT01341782
2

NCT00667576

NCT00990704

Known as 1alpha,25-dihydroxy-22-oxavitamin d3 ChEMBL registry synonym — accepted as the source's own label CHEMBL333950
Known as 22-oxacalcitriol ChEMBL registry synonym — accepted as the source's own label CHEMBL333950
Known as Oxarol ChEMBL registry synonym — accepted as the source's own label CHEMBL333950
Known as Prezios ChEMBL registry synonym — accepted as the source's own label CHEMBL333950
Known as SCH 209579 ChEMBL registry synonym — accepted as the source's own label CHEMBL333950
Modality Small molecule CHEMBL333950
Route Intravenous Intravenous administration 3 times a week immediately before completion of dialysis” NCT00990704